Last updated 7 months ago
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
121 patients around the world
Available in United States, Brazil, Spain
Telios Pharma, Inc.
2Research sites
121Patients around the world
This study is for people with
Myeloproliferative syndromes
Myelofibrosis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Adults ≥18 years of ageConfirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteriaPalpable spleen measuring ≥5 cm below the LLCM or spleen volume of ≥450 cm³ by MRI or CT scan assessmentEastern Cooperative Oncology Group (ECOG) performance status of ≤2Adequate hematologic, hepatic, and renal functions
- Prior treatment with any BTK or BMX inhibitorsCohorts 1 and 2 - Prior treatment with JAKi within 21 days of the Screening MRI/CT scan. Subjects in Cohort 3 must not have received JAKiPrior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment
Sites
Hospital de Clínicas de Porto Alegre - HCPA/UFRGS
Recruiting
Instituto de Ensino e Pesquisa São Lucas
Recruiting
SponsorTelios Pharma, Inc.
Study typeInterventional
Conditions
Myelofibrosis
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04655118
